Intra-Cellular Therapies Inc. (ITCI) SVP Sells $20,583.45 in Stock

Intra-Cellular Therapies Inc. (NASDAQ:ITCI) SVP Kimberly E. Vanover sold 1,185 shares of the firm’s stock in a transaction dated Friday, January 5th. The stock was sold at an average price of $17.37, for a total value of $20,583.45. Following the sale, the senior vice president now directly owns 26,803 shares of the company’s stock, valued at $465,568.11. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Shares of Intra-Cellular Therapies Inc. (NASDAQ ITCI) traded up $0.47 during trading on Friday, hitting $18.87. The stock had a trading volume of 435,257 shares, compared to its average volume of 660,678. Intra-Cellular Therapies Inc. has a 1-year low of $7.85 and a 1-year high of $22.67. The firm has a market capitalization of $1,040.00, a P/E ratio of -8.62 and a beta of 0.72.

Intra-Cellular Therapies (NASDAQ:ITCI) last announced its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.53) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.53). The business had revenue of $0.03 million during the quarter, compared to the consensus estimate of $0.06 million. Intra-Cellular Therapies had a negative return on equity of 27.40% and a negative net margin of 28,038.35%. The business’s revenue for the quarter was up 675.0% on a year-over-year basis. During the same period in the previous year, the company posted ($0.70) earnings per share. equities analysts forecast that Intra-Cellular Therapies Inc. will post -2.13 earnings per share for the current fiscal year.

Several equities analysts have weighed in on ITCI shares. ValuEngine downgraded Intra-Cellular Therapies from a “sell” rating to a “strong sell” rating in a research report on Tuesday, December 5th. BidaskClub downgraded Intra-Cellular Therapies from a “sell” rating to a “strong sell” rating in a research report on Tuesday, December 12th. Zacks Investment Research downgraded Intra-Cellular Therapies from a “buy” rating to a “hold” rating in a research report on Tuesday, October 17th. Canaccord Genuity started coverage on Intra-Cellular Therapies in a research report on Friday, December 15th. They issued a “buy” rating and a $31.00 target price for the company. Finally, SunTrust Banks raised Intra-Cellular Therapies from a “hold” rating to a “buy” rating in a research report on Wednesday, November 8th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and eight have given a buy rating to the company’s stock. Intra-Cellular Therapies presently has an average rating of “Buy” and an average price target of $25.56.

A number of hedge funds have recently bought and sold shares of the stock. Rhumbline Advisers lifted its stake in Intra-Cellular Therapies by 3.5% during the second quarter. Rhumbline Advisers now owns 43,296 shares of the biopharmaceutical company’s stock worth $538,000 after purchasing an additional 1,455 shares during the last quarter. Nationwide Fund Advisors lifted its stake in Intra-Cellular Therapies by 8.1% during the second quarter. Nationwide Fund Advisors now owns 27,928 shares of the biopharmaceutical company’s stock worth $347,000 after purchasing an additional 2,099 shares during the last quarter. Voya Investment Management LLC lifted its stake in Intra-Cellular Therapies by 16.0% during the second quarter. Voya Investment Management LLC now owns 16,911 shares of the biopharmaceutical company’s stock worth $210,000 after purchasing an additional 2,338 shares during the last quarter. SG Americas Securities LLC lifted its stake in Intra-Cellular Therapies by 45.9% during the third quarter. SG Americas Securities LLC now owns 12,060 shares of the biopharmaceutical company’s stock worth $190,000 after purchasing an additional 3,794 shares during the last quarter. Finally, Teachers Advisors LLC lifted its stake in Intra-Cellular Therapies by 7.3% during the second quarter. Teachers Advisors LLC now owns 62,615 shares of the biopharmaceutical company’s stock worth $778,000 after purchasing an additional 4,238 shares during the last quarter. Hedge funds and other institutional investors own 74.47% of the company’s stock.

WARNING: This article was first reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this article on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://ledgergazette.com/2018/01/13/kimberly-e-vanover-sells-1185-shares-of-intra-cellular-therapies-inc-itci-stock.html.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS).

Insider Buying and Selling by Quarter for Intra-Cellular Therapies (NASDAQ:ITCI)

Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply